Abstracts tagged "Scleroderma"

Abstract Number: 1236 • ACR Convergence 2024
A Novel Role for Artificial Intelligence in Detecting Distinctive Scleroderma Facial Features
yossra suliman¹ and daniel Furst², ¹Assiut university hospital, assiut, Egypt, ²Pacific Arthritis Center, Inglewood
Background/Purpose: Scleroderma (SSc) is a rare autoimmune fibrosing disease with high rates of morbidity and mortality. Scleroderma is usually diagnosed by rheumatologists and/or dermatologists. However,…
Abstract Number: 1689 • ACR Convergence 2024
Pulmonary Function Test Reference Equations May Drive Inequitable Classification of Restrictive Lung Disease Severity in Systemic Sclerosis
Kamini Kuchinad¹, Rachel Wallwork², Matthew Lammi³, Christopher Mecoli¹, Julie Paik¹, Fredrick Wigley⁴, Robert Wise¹, Laura Hummers⁵, Ami Shah⁶ and Ji Soo Kim¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University, Towson, MD, ³Johns Hopkins University Division of Pulmonary and Critical Care Medicine, Baltimore, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Black individuals with systemic sclerosis (SSc) have an increased frequency and severity of interstitial lung disease (ILD) as compared to their White counterparts. Pulmonary…
Abstract Number: 1867 • ACR Convergence 2024
RNA Polymerase III Specific CD8+ T Cells at the Interface Between Scleroderma and Cancer
Eleni Tiniakou¹, Mekha Thomas², Ami Shah³, Fredrick Wigley⁴, Livia Casciola-Rosen², Kellie Smith², Antony Rosen² and Erika Darrah², ¹Johns Hopkins University, Lutherville Timonium, MD, ²Johns Hopkins University, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD
Background/Purpose: Increasing evidence suggests an immunologic link between cancer and autoimmunity. Systemic sclerosis (SSc), offers a unique opportunity to study the evolution of naturally occurring…
Abstract Number: 2465 • ACR Convergence 2024
Subclinical Loss of Lung Volumes in Very Early SSc: Evidence from Two Independent Cohorts in EUSTAR
Vishal Kakkar¹, Stefano Di Donato², Silvia Bellando-Randone³, Riccardo Bixio⁴, Marco Matucci-Cerinic⁵, Yannick Allanore⁶ and Francesco Del Galdo¹, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University of Verona, Verona, Verona, Italy, ⁵University San Raffaele Milano, Milano, Milan, Italy, ⁶Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) remains as the major driver of mortality in systemic sclerosis (SSc). The literature indicates that at the time of diagnosis…
Abstract Number: 0309 • ACR Convergence 2024
Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Omar Hamdan¹, Roa'a Alshajrawi¹, Qais Mussa¹, Yazeed Alajlouni¹, Yazan Dabbah¹, Rawan Fratekh¹, Yousef Al-Mabrouk², Shatha Al-Mabrok² and Ahmad A. Toubasi¹, ¹University of Jordan, Amman, Jordan, ²Mansoura University, Al Mansoura, Egypt
Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
Abstract Number: 0706 • ACR Convergence 2024
Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension
Carleigh Zahn¹, Scott Visovatti², Rosemary Gedert¹, Suiyuan Huang¹, Victor Moles¹, Amber Young¹, Vallerie McLaughlin¹ and Dinesh Khanna¹, ¹University of Michigan, Ann Arbor, MI, ²The Ohio State University, Columbus
Background/Purpose: Pulmonary hypertension (PH) is a leading cause of mortality in systemic sclerosis (SSc). We launched an IRB approved prospective study (NOVEL) in 2013 at…
Abstract Number: 1244 • ACR Convergence 2024
Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO
Alain Lescoat¹, Yen Chen², Rosemary Gedert², Neda Kortam², Nadia Vann², David Cella³, Sara Shaunfield⁴, Susan Murphy⁵ and Dinesh Khanna², ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³Northwestern University, Chicago, IL, ⁴Northwestern University, Chicago, ⁵University of Michigan, Plymouth, MI
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that…
Abstract Number: 1692 • ACR Convergence 2024
Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Trinitee Oliver¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin⁶ and Richard Ainsworth⁶, ¹Cedars-Sinai Medical Center, Hawthorne, CA, ²University of California, San Francisco, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
Abstract Number: 1914 • ACR Convergence 2024
Racial and Ethnic Differences in the Prevalence of Disease Features in Systemic Sclerosis
Harry Hurley¹, Davina Chen², Xianhong Xie³, Manpreet Parmar⁴ and Bibi Ayesha⁵, ¹Albert Einstein College of Medicine, Maplewood, NJ, ²Montefiore Medical Center, New Rochelle, NY, ³Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore, Bronx, NY, ⁵Montefiore Medical Center, Metuchen, NJ
Background/Purpose: Systemic sclerosis (SSc) is a chronic, systemic autoimmune disease with a higher prevalence among women and racial/ethnic minority groups in the US. Despite the…
Abstract Number: 2468 • ACR Convergence 2024
Audio-Guided Imagery Positively Impacted Patients with Raynaud’s Phenomenon Associated Connective Tissue Disease
Cristina Padilla¹, Veena Katikineni², Yongseok Park¹, Leigh Freno³, Maureen Laffoon⁴ and Robyn Domsic⁵, ¹University of Pittsburgh, Pittsburgh, PA, ²Providence, Victorville, CA, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴UPMC, Pittsburgh, PA, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is characterized as episodic color changes of the digits occurring with exposure to cold environments, sudden temperature decreases, and emotional stress. …
Abstract Number: 0361 • ACR Convergence 2024
Maternal and Fetal Outcomes in Those with Autoimmune Connective Tissue Disease
Nada Alrifai¹, Anushree Puttur², Laith Alhuneafat³, Fares Ghanem⁴, yadhu Dhital², Ahmad Jabri⁵ and David Feinstein⁶, ¹Cooper University Hospital, Cherry Hill, NJ, ²Allegheny Health Network, Pittsburgh, PA, ³University of Minnesota, Minneapolis, MN, ⁴Southern Illinois University, Springfield, IL, ⁵Henry Ford, Detroit, MI, ⁶Cooper University, Camden, NJ
Background/Purpose: Autoimmune connective tissue diseases (CTD) predominantly affect women during their reproductive years. CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic…
Abstract Number: 0710 • ACR Convergence 2024
High S100A4 Levels Associate with Inflammation and Vasculopathy in Systemic Sclerosis
Adela-Cristina Sarbu¹, Håvard Fretheim², Ladislav Šenolt³, Henriette Didriksen⁴, Cosimo Bruni⁵, Marco Sprecher⁶, Thor Ueland⁷, Jonas Hallén⁸, Rizwan Hussain⁹, Jörg Klingelhöfer¹⁰, Michal Tomcik¹¹, Yannick Allanore¹², Oliver Distler¹³ and Anna-Maria Hoffmann-Vold², ¹University Hospital Zurich, University of Zurich, Department of Rheumatology, Bern, Switzerland, ²Oslo University Hospital, Oslo, Norway, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Oslo University Hospital, Moss, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitätsspital Zürich (University Hospital Zurich), Zürich, Switzerland, ⁷Research Institute of Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, ⁸Arxx Therapeutics, Oslo, Norway, Oslo, Norway, ⁹Agiana Therapeutics, Oslo, Norway, Oslo, Norway, ¹⁰Calluna Pharma, Oslo, Norway, Oslo, Norway, ¹¹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, ¹²Université Paris Cité, Paris, France, ¹³Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: S100A4, a member of the S100 protein family, is implicated in various cellular processes. In systemic sclerosis (SSc), S100A4 is believed to contribute to…
Abstract Number: 1559 • ACR Convergence 2024
Vectorcardiography for Identification of Systemic Sclerosis Patients at Risk for Pulmonary Hypertension
S. Ahmed¹, Eva Hoekstra², Katie van der Wouden², Sum-Che Man², Kees Swenne², Madelon Vonk³, Anna-Maria Hoffmann-Vold⁴, Cosimo Bruni⁵, Udo Mulder⁶, Thomas Huizinga⁷, H.W. Vliegen² and Jeska de Vries-Bouwstra², ¹Leiden University Medical Centre, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Oslo University Hospital, Oslo, Norway, ⁵University of Zurich, Zurich, Switzerland, ⁶Universitair Medisch Centrum Groningen, Groningen, Netherlands, ⁷Department of Rheumatology, Leiden University, Leiden, Netherlands
Background/Purpose: Pulmonary hypertension (PH) in SSc causes significant disease burden and requires invasive diagnosis with right heart catheterization (RHC). Comprehensive work-up is needed to identify…
Abstract Number: 1814 • ACR Convergence 2024
Understanding Monocyte Derived Macrophages in the Skin of SSc Patients Through Single Cell Analysis of Blister Fluid Immune Cell Populations
Sandra Lopez Garces¹, Tamara Searle², Siyu Zhang¹, Henry Lopez³, Isra Elhussin⁴, Clayton Yates⁴, David Abraham⁵, Christopher Denton⁶, Bahja Ahmed Abdi¹ and Richard Stratton⁷, ¹University College London, London, United Kingdom, ²Imperial College London, London, United Kingdom, ³Riptide Bioscience Inc, Bethesda, MD, ⁴Johns Hopkins University, Baltimore, MD, ⁵UCL, London, United Kingdom, ⁶University College London, Northwood, United Kingdom, ⁷UCL, London, England, United Kingdom
Background/Purpose: Cells of the monocyte-macrophages (Mφ) are key players in the pathogenesis of systemic sclerosis (SSc), contributing to inflammation and fibrosis. To advance beyond the…
Abstract Number: 1920 • ACR Convergence 2024
Admixture Mapping and Gene-Based Analysis Identifies Rare Variants in Genes in the IL-13 and TGFβ Signaling Pathways in African Americans with Systemic Sclerosis
Jordan Hicks¹, Daniel Shriner², Ami Shah³, Maureen Mayes⁴, Ayo P. Doumatey², Amy R. Bentley¹, Robyn Domsic⁵, Thomas Medsger, Jr⁶, Paula Ramos⁷, Richard Silver⁸, Virginia Steen⁹, John Varga¹⁰, Vivien Hsu¹¹, Lesley Ann Saketkoo¹², Dinesh Khanna¹⁰, Elena Schiopu¹³, Jessica Gordon¹⁴, Lindsey Criswell¹⁵, Heather Gladue¹⁶, Chris Derk¹⁷, Elana Bernstein¹⁸, S. Louis Bridges¹⁴, Victoria Shanmugam¹⁹, Lorinda Chung²⁰, Suzanne Kafaja²¹, Reem Jan²², Marcin Trojanowski²³, Avram Goldberg²⁴, Benjamin Korman²⁵, James W. Thomas²⁶, Elaine Remmers²⁷, Adebowale Adeyemo², Charles Rotimi², Fredrick Wigley²⁸, Francesco Boin²⁹, Daniel Kastner³⁰ and Pravitt Gourh³¹, ¹National institute of Health, Bethesda, MD, ²Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴UTHealth Houston Division of Rheumatology, Houston, TX, ⁵Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Verona, PA, ⁷Medical University of South Carolina, Charleston, SC, ⁸Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, ⁹Georgetown University School of Medicine, Washington, DC, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Department of Medicine, Rheumatology Division, Rutgers-RWJ Medical School, South Plainfield, NJ, ¹²New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ¹³Division of Rheumatology, Medical College of Georgia at Augusta University, Martinez, GA, ¹⁴Division of Rheumatology, Weill Cornell Medical College, New York, NY, ¹⁵Genomics of Autoimmune Rheumatic Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, Bethesda, MD, ¹⁶Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹⁷Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁸Division of Rheumatology, Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, ¹⁹NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, ²⁰Stanford University, Woodside, CA, ²¹Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²²Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL, ²³Department of Rheumatology, Boston University School of Medicine, Boston, MA, ²⁴NYU Langone Health - NYU Hospital for Joint Diseases, Lake Success, NY, ²⁵University of Rochester, Rochester, NY, ²⁶NIH Intramural Sequencing Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁷Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁸Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ²⁹Cedars-Sinai Medical Center, Los Angeles, CA, ³⁰National Human Genome Research Institute, Bethesda, MD, ³¹National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, Bethesda, MD
Background/Purpose: There are significant racial disparities in systemic sclerosis (SSc), with an increased disease burden and worse outcomes among African American (AA) individuals. Reasons for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.